BIO 2009

• The biggest news of the day is BIO. Yeah, it’s that time again, and while this year promises to be lackluster event relative to past years, there’s still projected to be a decent size turnout of 17,000 in Atlanta. The company presentations also start tomorrow with over 180 biotechs and pharmas giving their pitch. Some of the more interesting ones, for us at least, are Amgen, Cell Therapeutics, Crucell, Genentech, Nektar Therapeutics, PTC Therapeutics and a few others. [BIO Annual Meeting Website]

• European biotechs are falling behind US biotechs in terms of investment and innovation. [Financial Times]

• BIO also tackling diversity in the workplace. [Georgia Public Broadcasting]

• BIO 2009 is a different monster – playing a different game. [Wisconsin Technology Network]

ASCO Watch 2009

• Oncothyreon will be presenting data on Stimuvax®, PX-866 and PX-12. [Yahoo!Finance]

• Keryx Biopharmaceuticals will be report data from phase 2 studies on KRX-0401 in treating advanced renal cell carcinoma, colorectal cancer and gastrointestinal stromal tumors (GIST). [Yahoo!Finance]

Other Stuff

• Burill tells us what we already know: It’s a Graveyard out there! [The Burrill Report]

• FDA says thumbs up for J&J’s Risperdal Consta as both monotherapy and adjunctive therapy in the maintenance treatment of bipolar I disorder. [Pharmalive]

• The FDA has accepted MannKind’s Afresa NDA. [Los Angeles Business Journal]

• Optimer’s fidaxomicin doesn’t impress analysts, shares drop. [WSJ]

• Finally, moreMore proxy advisers are backing Icahn’s and Eastbourne’s Amylin Board nominees. [WSJ]

And that’s that…

Image from patentdocs

Related Posts

No related posts.